- Home
- LTRN vs STTK Comparison
LTRN vs STTK Comparison
Compare LTRN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- STTK
- Stock Information
- Founded
- LTRN 2013
- STTK 2016
- Country
- LTRN United States
- STTK United States
- Employees
- LTRN N/A
- STTK N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- STTK Health Care
- Exchange
- LTRN Nasdaq
- STTK Nasdaq
- Market Cap
- LTRN 36.1M
- STTK 37.6M
- IPO Year
- LTRN 2020
- STTK 2020
- Fundamental
- Price
- LTRN $3.32
- STTK $1.14
- Analyst Decision
- LTRN Strong Buy
- STTK Hold
- Analyst Count
- LTRN 1
- STTK 4
- Target Price
- LTRN $25.00
- STTK $3.00
- AVG Volume (30 Days)
- LTRN 67.8K
- STTK 102.4K
- Earning Date
- LTRN 05-15-2025
- STTK 07-31-2025
- Dividend Yield
- LTRN N/A
- STTK N/A
- EPS Growth
- LTRN N/A
- STTK N/A
- EPS
- LTRN N/A
- STTK N/A
- Revenue
- LTRN N/A
- STTK $4,606,000.00
- Revenue This Year
- LTRN N/A
- STTK N/A
- Revenue Next Year
- LTRN N/A
- STTK N/A
- P/E Ratio
- LTRN N/A
- STTK N/A
- Revenue Growth
- LTRN N/A
- STTK 69.65
- 52 Week Low
- LTRN $2.55
- STTK $0.69
- 52 Week High
- LTRN $6.12
- STTK $7.49
- Technical
- Relative Strength Index (RSI)
- LTRN 47.70
- STTK 56.02
- Support Level
- LTRN $2.85
- STTK $0.98
- Resistance Level
- LTRN $3.48
- STTK $1.13
- Average True Range (ATR)
- LTRN 0.26
- STTK 0.10
- MACD
- LTRN 0.01
- STTK 0.01
- Stochastic Oscillator
- LTRN 53.41
- STTK 84.85
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.